BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 15274198)

  • 1. Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation.
    Lee JJ; Kook H; Park MS; Nam JH; Choi BH; Song WH; Park KS; Lee IK; Chung IJ; Hwang TJ; Kim HJ
    J Clin Apher; 2004; 19(2):66-70. PubMed ID: 15274198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of leukemic-cell-specific cytotoxic T lymphocytes by autologous monocyte-derived dendritic cells presenting leukemic cell antigens.
    Lee JJ; Park MS; Park JS; Kang HK; Kim SK; Nguyen Pham TN; Zhu XW; Cho D; Nam JH; Kim YJ; Rhee JH; Chung IJ; Kim HJ
    J Clin Apher; 2006 Oct; 21(3):188-94. PubMed ID: 16570260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of the concentration of autologous serum for generation of leukemic dendritic cells from acute myeloid leukemic cells for clinical immunotherapy.
    Choi BH; Kang HK; Park JS; Kim SK; Pham TN; Zhu XW; Cho D; Nam JH; Chung IJ; Kim YJ; Rhee JH; Kim HJ; Lee JJ
    J Clin Apher; 2006 Dec; 21(4):233-40. PubMed ID: 17120232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
    Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
    J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.
    Li L; Giannopoulos K; Reinhardt P; Tabarkiewicz J; Schmitt A; Greiner J; Rolinski J; Hus I; Dmoszynska A; Wiesneth M; Schmitt M
    Int J Oncol; 2006 Apr; 28(4):855-61. PubMed ID: 16525634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors.
    Suminoe A; Matsuzaki A; Hattori H; Koga Y; Hara T
    Pediatr Transplant; 2009 Sep; 13(6):746-53. PubMed ID: 19067917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [T-cell immunity against autologous leukemic cell mediated by in vitro bone marrow-derived dendritic cell from patients with acute myeloid leukemia in complete remission].
    He X; You S; Bian S
    Zhonghua Xue Ye Xue Za Zhi; 2001 Dec; 22(12):629-32. PubMed ID: 16200709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The functional immaturity of dendritic cells can be relevant to increased tolerance associated with cord blood transplantation.
    Encabo A; Solves P; Carbonell-Uberos F; Miñana MD
    Transfusion; 2007 Feb; 47(2):272-9. PubMed ID: 17302774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells.
    Köhler T; Plettig R; Wetzstein W; Schmitz M; Ritter M; Mohr B; Schaekel U; Ehninger G; Bornhäuser M
    Stem Cells; 2000; 18(2):139-47. PubMed ID: 10742386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The maturation-dependent production of interleukin-16 is impaired in monocyte-derived dendritic cells from atopic dermatitis patients but is restored by inflammatory cytokines TNF-alpha and IL-1beta.
    Reich K; Hugo S; Middel P; Blaschke V; Heine A; Neumann C
    Exp Dermatol; 2004 Dec; 13(12):740-7. PubMed ID: 15560757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of cytotoxic donor CD8+ T cells against relapsing leukemic cells following allogeneic transplantation by stimulation with leukemic cell- or leukemic lysate pulsed donor cell-derived dendritic cells.
    Lee JJ; Nam CE; Nam JH; Lee HC; Chung IJ; Park MS; Choi BH; Song WH; Lee IK; Park KS; Kook H; Hwang TJ; Takei M; Takaue Y; Kim HJ
    Leuk Res; 2004 May; 28(5):517-24. PubMed ID: 15068905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: application to active immunotherapy.
    Royer PJ; Bougras G; Ebstein F; Leveque L; Tanguy-Royer S; Simon T; Juge-Morineau N; Chevallier P; Harousseau JL; Gregoire M
    Exp Hematol; 2008 Mar; 36(3):329-39. PubMed ID: 18207305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonleukemic myeloid dendritic cells obtained from autologous stem cell products elicit antileukemia responses in patients with acute myeloid leukemia.
    Serrano-López J; Sanchez-Garcia J; Serrano J; Alvarez-Rivas MA; Garcia-Castellano JM; Roman-Gomez J; de la Rosa O; Herrera-Arroyo C; Torres-Gomez A
    Transfusion; 2011 Jul; 51(7):1546-55. PubMed ID: 21303373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential.
    Liepert A; Grabrucker C; Kremser A; Dreyssig J; Ansprenger C; Freudenreich M; Kroell T; Reibke R; Tischer J; Schweiger C; Schmid C; Kolb HJ; Schmetzer H
    Cell Immunol; 2010; 265(1):23-30. PubMed ID: 20663492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes.
    Kufner S; Fleischer RP; Kroell T; Schmid C; Zitzelsberger H; Salih H; de Valle F; Treder W; Schmetzer HM
    Cancer Immunol Immunother; 2005 Oct; 54(10):953-70. PubMed ID: 15789235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia.
    Schmitt A; Li L; Giannopoulos K; Greiner J; Reinhardt P; Wiesneth M; Schmitt M
    Transfusion; 2008 May; 48(5):861-70. PubMed ID: 18208411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial.
    Van Driessche A; Van de Velde AL; Nijs G; Braeckman T; Stein B; De Vries JM; Berneman ZN; Van Tendeloo VF
    Cytotherapy; 2009; 11(5):653-68. PubMed ID: 19530029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monocyte-derived dendritic cells from HLA-matched allogeneic donors showed a greater ability to induce leukemic cell-specific T cells in comparison to leukemic cell-derived dendritic cells or monocyte-derived dendritic cells from AML patients.
    Lee JJ; Choi BH; Kang HK; Kim SK; Nam JH; Yang DH; Kim YK; Kim HJ; Chung IJ
    Leuk Res; 2008 Nov; 32(11):1653-60. PubMed ID: 18501426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monocyte-derived dendritic cells from chronic HCV patients are not infected but show an immature phenotype and aberrant cytokine profile.
    Gelderblom HC; Nijhuis LE; de Jong EC; te Velde AA; Pajkrt D; Reesink HW; Beld MG; van Deventer SJ; Jansen PL
    Liver Int; 2007 Sep; 27(7):944-53. PubMed ID: 17696933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells.
    Draube A; Beyer M; Wolf J
    Eur J Haematol; 2008 Oct; 81(4):281-8. PubMed ID: 18573171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.